Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Share this page:

Title

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Subject

Description

Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).

Source

Doria-Rose, Nicole, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, Bob C. Lin, Sijy O’Dell, Stephen D. Schmidt, Alicia T. Widge, Venkata-Viswanadh Edara, Evan J. Anderson, Lilin Lai, Katharine Floyd, Nadine G. Rouphael, Veronika Zarnitsyna, Paul C. Roberts, Mamodikoe Makhene, Wendy Buchanan, Catherine J. Luke, John H. Beigel, Lisa A. Jackson, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Jim Albert, and Pratap Kunwar.

Date Last Updated (Year-Month-Day)

2021-04-06

Citation

Doria-Rose, Nicole, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, Bob C. Lin, Sijy O’Dell, Stephen D. Schmidt, Alicia T. Widge, Venkata-Viswanadh Edara, Evan J. Anderson, Lilin Lai, Katharine Floyd, Nadine G. Rouphael, Veronika Zarnitsyna, Paul C. Roberts, Mamodikoe Makhene, Wendy Buchanan, Catherine J. Luke, John H. Beigel, Lisa A. Jackson, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Jim Albert, and Pratap Kunwar. 2021. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." New England Journal of Medicine.

Accessibility

Free online on NEJM